No Data
Express News | Tandem Diabetes Care Recalls Version 2.7 Of Apple iOS T:Connect Mobile App Used With T:Slim X2 Insulin Pump With Control-IQ Technology
Express News | FDA: Tandem Diabetes Care Recall of Version 2.7 of Apple iOS T:Connect Mobile App Is a Correction, Not a Product Removal
Express News | FDA: Tandem Diabetes Care Recall of Version 2.7 of Apple iOS T:Connect Mobile App Prompted by Software Problem Leading to Pump Battery Depletion
Express News | FDA: Tandem Diabetes Care Recalls Version 2.7 of Apple iOS T:Connect Mobile App Used With T:Slim X2 Insulin Pump With Control-Iq Technology
Research Alert: CFRA Keeps Hold Opinion On Shares Of Tandem Diabetes Care, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target price to $48 from $36
Tandem Diabetes Care Is Maintained at Overweight by Barclays
Tandem Diabetes Care Is Maintained at Overweight by Barclays